Volume 4.24 | Jul 3

2020-03-07 | HCN 4.24
Hepatic Cell News by STEMCELL Technologies
Vol. 4.24 – 3 July, 2020

miR‐125b Loss Activated HIF1α/pAKT Loop, Leading to Trans‐Arterial Chemoembolization Resistance in Hepatocellular Carcinoma

Scientists aimed to identify key molecular signatures and related pathways leading to hepatocellular carcinoma resistance to trans‐arterial chemoembolization (TACE), with the hope of developing effective approaches in pre‐selecting patients with survival benefit from TACE.


How to prioritize and manage your research projects
PUBLICATIONSRanked by the impact factor of the journal

Attenuating the EGFR‐ERK‐SOX9 Axis Promotes Liver Progenitor Cell‐Mediated Liver Regeneration in Zebrafish

Researchers found that suppression of EGFR signaling promoted liver progenitor cell‐to‐hepatocyte differentiation via the MEK‐ERK‐SOX9 cascade.


Doublecortin-Like Kinase 1 Promotes Hepatocyte Clonogenicity and Oncogenic Programming via Non-Canonical β-Catenin-Dependent Mechanism

Spheroids derived from doublecortin-like kinase 1 (DCLK1)-overexpressing hepatoma cells showed high level expression of active β-catenin, α-fetoprotein, and SOX9, suggesting that DCLK1 overexpression induced clonogenicity and dedifferentiated phenotypes in hepatoma cells.
[Scientific Reports]

Full Article

Decreased miR-200b-3p in Cancer Cells Leads to Angiogenesis in HCC by Enhancing Endothelial ERG Expression

Researchers investigated whether hepatocyte-derived miR-200b-3p governed angiogenesis in hepatocellular carcinoma (HCC) by targeting endothelial erythroblast transformation-specific-related gene (ERG).
[Scientific Reports]

Full Article

Hepatic Stellate Cell-Specific Platelet-Derived Growth Factor Receptor α Loss Reduces Fibrosis and Promotes Repair following Hepatocellular Injury

While no major difference was observed after bile duct ligation or 3,5-diethoxycarbonyl-1,4-dihydrocollidine, platelet-derived growth factor receptor α loss in hepatic stellate cells (HSCs) led to a significant albeit transient reduction in fibrosis after CCl4 injury, associated with increased HSC death and reduced migration.
[American Journal of Pathology]


MicroRNA-375 Represses Tumor Angiogenesis and Reverses Resistance to Sorafenib in Hepatocarcinoma

The authors identified that the expression of the tumor-suppressive miRNA miR-375 was significantly induced in hepatoma cells treated with sorafenib, and miR-375 could exert its antiangiogenic effect partially via platelet-derived growth factor C inhibition.
[Cancer Gene Therapy]

Full Article

Human Hepatic In Vitro Models Reveal Distinct Anti-NASH Potencies of PPAR Agonists

Investigators reproduced key non-alcoholic steatohepatitis (NASH) characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 cells to multiple factors that play a role in the onset of NASH.
[Cell Biology and Toxicology]


Fibrillar Collagen Type I Participates in the Survival and Aggregation of Primary Hepatocytes Cultured on Soft Hydrogels

Researchers evaluated the role of fibrillar collagens and basement membrane-associated matrix on actin cytoskeleton organization and the function of rat primary hepatocytes cultured on soft elastic polyacrylamide hydrogels.
[Bioinspiration & Biomimetics]


A Licorice Roots Extract Induces Apoptosis and Cell Cycle Arrest and Improves Metabolism via Regulating MiRNAs in Liver Cancer Cells

Scientists investigated the effect of licorice roots extract on some metabolic pathways and their regulating miRNAs in hepatocellular carcinoma cells.
[Nutrition and Cancer-An International Journal]


Watch 'collaborating to accelerate COVID-19 research'

Induced Pluripotent Stem Cells for the Treatment of Liver Diseases: Novel Concepts

The authors conclude the current state of efforts to derive human induced pluripotent stem cells for potential use in the modeling and treatment of liver disease.
[Cells Tissues Organs]



BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

BeiGene, Ltd. announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application of BeiGene’s anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated unresectable hepatocellular carcinoma, the most common form of liver cancer.
[BeiGene, Ltd. (GlobeNewswire, Inc.)]

Press Release

DURECT Corporation Announces Initiation of Patient Recruitment in Phase II Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

DURECT Corporation announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase II study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury.
[DURECT Corporation]

Press Release

Amidst Uncertainty, Flexibility Is Key in Higher Ed, Faculty Say

Life sciences professors and other staff make contingency plans for more coronavirus-related disruptions in the coming school year.
[The Scientist]



Keystone eSymposia | Advances in Cancer Immunotherapy

August 17 – August 19

> See All Events


Oligonucleotide Chemist – Liver and CNS

Deep Genomics – Toronto, Ontario, Canada

Postdoctoral Scholarship – Molecular Metabolism

University of Gothenburg – Gothenburg, Sweden

Postdoctoral Research Scientist – Liver Diseases

Columbia University Medical Center – New York, New York, United States

Postdoctoral Scientist – Gene Editing in Liver Disease

Beam Therapeutics – Cambridge, Massachusetts, United States

Associate Professor – Hepatology

Yale University – New Haven, Connecticut, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Hepatic Cell News Twitter